Effect of Pamidronate Treatment in Children with Polyostotic Fibrous Dysplasia of Bone

HORACIO PLOTKIN, FRANK RAUCH, LEONID ZEITLIN, CRAIG MUNNS, ROSE TRAVERS, AND FRANCIS H. GLORIEUX

Genetics Unit, Shriners Hospital for Children, Québec, Canada H3G 1A6; and the Departments of Surgery and Pediatrics, McGill University, Montréal, Québec, Canada H3H 1P3

Intravenous infusions with the bisphosphonate compound pamidronate decrease bone pain and reportedly can lead to refilling of dysplastic lesions in adults with fibrous dysplasia (FD) of bone. Here we describe the effects of this treatment approach in 18 children and adolescents (age at start of therapy, 6.2–17.5 yr; eight girls) with polyostotic FD, who received pamidronate for 1.2–9.1 yr (median, 3.8 yr). Treatment cycles with pamidronate (1–1.5 mg/kg/d on 3 consecutive days) were given every 4 months. Levels of serum alkaline phosphatase and urinary collagen type I N-telopeptide were elevated at baseline and decreased continuously during the first 3 yr of therapy. There was no radiographic evidence of filling of lytic lesions or thickening of the bone cortex surrounding the lesions in any patient. Histomorphometric results in dysplastic bone tissue of patients receiving pamidronate (n = 7; time of therapy, 1.4–4.8 yr) were similar to those of patients without medical therapy (n = 9). No serious side effects were noted. In conclusion, pamidronate therapy appears to be safe in children and adolescents with polyostotic FD. However, we found no clear evidence that pamidronate has an effect on dysplastic lesions in such patients. (J Clin Endocrinol Metab 88: 4569–4575, 2003)
Bone (Table 1). The three girls had precocious puberty that had been treated before the start of pamidronate. Treatment of precocious puberty was surgical in one case (excision of an autonomous ovarian cyst) and included aromatase inhibitors (testolactone) in the two others. The boy had only café-au-lait spots. In the other 14 patients, endocrinologic evaluation did not reveal abnormalities and no symptoms of endocrine dysfunction developed during the course of follow-up. Eleven patients had sustained 1–14 fractures before treatment with pamidronate was started. Clinically, six patients had marked limb deformity, and two of them had panostotic disease (16). All patients presented with pain at the site of the lesions.

Mobility was evaluated for each child by physiotherapists experienced in the care of children with bone diseases. A 5-point score was used: 0, bed-wheelchair-bound; 1, walking with aids possible, but non-functional; 2, household walker, with/without aids; 3, neighborhood walker with/without aids; and 4, independent walker (17).

Informed consent was obtained in each instance from the legal guardian. The study protocol was approved by the ethics committee of the Shriners Hospital.

**Treatment**

The treatment protocol was similar to the schedule that we have been using for the treatment of osteogenesis imperfecta (18). Pamidronate was administered iv on 3 consecutive days in all patients. The first 3-d cycle consisted of a dose of 0.5 mg/kg on d 1 and 1 mg/kg on d 2 and 3. In subsequent cycles, the dose was 1–1.5 mg/kg daily for 3 d, the dose depending on the perceived treatment success. Pamidronate cycles were repeated every 4 months, as the clinical effect of a treatment cycle (reduction of bone pain, increase in stamina) appeared to diminish after this time. Each dose was diluted in 0.9% saline solution and administered slowly over 4 h. Calcium and vitamin D intake was maintained adequately according to the recommended daily allowance in all patients. All patients underwent physiotherapy and occupational therapy evaluation and support, including exercises and design of special devices for transportation and sitting.

**Follow-up**

Each patient was examined every 4 months. Biochemical measurements and bone densitometry were performed at every visit, and x-rays of involved sites were taken at a yearly interval. According to the treatment protocol, iliac bone biopsies were to be performed before the start of treatment and after 2 yr of therapy. As the biopsy specimens were preferably obtained during elective orthopedic procedures, the actual timing of the biopsy could deviate from the treatment protocol. In patients who did not require orthopedic interventions, specimens were obtained under general anesthesia in a procedure performed exclusively for this purpose. Biopsies were not performed in patients who presented an elevated risk for anesthesia.

**Biochemistry**

Serum total calcium, phosphate, creatinine and alkaline phosphatase activity were measured using colorimetric methods (Monarch; Instrumentation Laboratories Inc., Lexington, MA). Serum PTH concentrations (fragment 39–84) were determined by RIA (19). 25-OH vitamin D and 1,25-OH vitamin D were measured with RIAs (25-hydroxyvitamin D and 1,25-dihydroxyvitamin D Osteo SP; Incstar Corp., Stillwater, MN). Urinary calcium and creatinine were quantified colorimetrically. The bone resorption marker urinary cross-linked N-telopeptide of type I collagen (NTX) was quantified by ELISA (Osteomark; Ostex, Seattle, WA) on the second void sample of the morning. Results for urinary NTX/creatinine ratios were compared with published reference data (20). Patients were fasting at the time of blood and urine sampling.

**Bone densitometry**

Bone densitometry was performed in the anteroposterior direction at the lumbar spine (L1–L4) using a Hologic QDR 2000W or 4500A device (Hologic Inc., Waltham, MA). Volumetric bone mineral density (vBMD) was calculated as the ratio between bone mineral content (BMC) and the extrapolated external volume of the measured bones. This was done as described by Carter et al. (21) using the formula:

$$\text{vBMD} = \frac{\text{BMC}}{(\text{projection area})^{1.5}}$$

Age- and sex-specific mean values for projection area and vBMD in healthy children were calculated from published densitometric reference material (22). Results for BMC, projection area, and vBMD in FD patients were expressed as a percentage of these mean values for healthy children.

---

**TABLE 1. Clinical characteristics of patients at the start of treatment**

<table>
<thead>
<tr>
<th>No.</th>
<th>Sex</th>
<th>Age (yr)</th>
<th>Involved sites</th>
<th>Mobility score</th>
<th>Diagnosis</th>
<th>Duration of follow-up (yr)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>M</td>
<td>17.5</td>
<td>Panostotic; L radius; R femur; R tibia</td>
<td>2</td>
<td>PFD</td>
<td>9.1</td>
</tr>
<tr>
<td>2</td>
<td>M</td>
<td>11.8</td>
<td>Skull; R humerus; L femur; R tibia; L fibula</td>
<td>4</td>
<td>PFD</td>
<td>7.5</td>
</tr>
<tr>
<td>3</td>
<td>F</td>
<td>7.6</td>
<td>L radius; R femur; L tibia; R metatarsal II</td>
<td>4</td>
<td>MAS</td>
<td>1.2</td>
</tr>
<tr>
<td>4</td>
<td>M</td>
<td>11.6</td>
<td>Skull; R scapula; R humerus; R ulna; R thumb; L femur; L tibia</td>
<td>4</td>
<td>PFD</td>
<td>7.0</td>
</tr>
<tr>
<td>5</td>
<td>M</td>
<td>11.2</td>
<td>R femur; R fibula</td>
<td>2</td>
<td>MAS</td>
<td>5.8</td>
</tr>
<tr>
<td>6</td>
<td>F</td>
<td>10.5</td>
<td>Skull; L humerus; R humerus; R radius; R hand phalanges</td>
<td>4</td>
<td>PFD</td>
<td>1.9</td>
</tr>
<tr>
<td>7</td>
<td>M</td>
<td>13.9</td>
<td>R and L humerus, ulna, radius; Ribs; R and L femur, fibula</td>
<td>2</td>
<td>PFD</td>
<td>3.9</td>
</tr>
<tr>
<td>8</td>
<td>M</td>
<td>6.2</td>
<td>Panostotic</td>
<td>0</td>
<td>PFD</td>
<td>3.6</td>
</tr>
<tr>
<td>9</td>
<td>M</td>
<td>4.2</td>
<td>L orbita, L metacarpals, L femur, L tibia, L metatarsals</td>
<td>4</td>
<td>MAS</td>
<td>3.7</td>
</tr>
<tr>
<td>10</td>
<td>F</td>
<td>8.8</td>
<td>R femur, R tibia; R metatarsal II–IV</td>
<td>4</td>
<td>PFD</td>
<td>1.3</td>
</tr>
<tr>
<td>11</td>
<td>M</td>
<td>11.5</td>
<td>R and L femur, fibula</td>
<td>4</td>
<td>PFD</td>
<td>4.2</td>
</tr>
<tr>
<td>12</td>
<td>F</td>
<td>9.8</td>
<td>R and L femur</td>
<td>0</td>
<td>PFD</td>
<td>3.7</td>
</tr>
<tr>
<td>13</td>
<td>F</td>
<td>11.1</td>
<td>R and L femur</td>
<td>4</td>
<td>PFD</td>
<td>2.0</td>
</tr>
<tr>
<td>14</td>
<td>M</td>
<td>13.1</td>
<td>L humerus; L ulna; L phalanges; R and L femur, tibia</td>
<td>4</td>
<td>PFD</td>
<td>6.8</td>
</tr>
<tr>
<td>15</td>
<td>F</td>
<td>9.2</td>
<td>Skull; R and L femur; L tibia; L fibula</td>
<td>4</td>
<td>PFD</td>
<td>6.2</td>
</tr>
<tr>
<td>16</td>
<td>F</td>
<td>8.5</td>
<td>R femur, R fibula</td>
<td>4</td>
<td>PFD</td>
<td>2.6</td>
</tr>
<tr>
<td>17</td>
<td>M</td>
<td>4.0</td>
<td>R and L femur, tibia</td>
<td>4</td>
<td>PFD</td>
<td>4.1</td>
</tr>
<tr>
<td>18</td>
<td>F</td>
<td>6.4</td>
<td>R femur, R tibia</td>
<td>4</td>
<td>MAS</td>
<td>3.3</td>
</tr>
</tbody>
</table>

R, Right; L, left; PFD, polyostotic fibrous dysplasia; MAS, McCune-Albright syndrome.
Radiographic evaluation

For quantitative evaluation of dysplastic lesions, we compared x-rays that were obtained at the start of treatment to those from the last follow-up visit. Radiographs were screened for dysplastic lesions that were sufficiently well delimited to allow for measurement of lesion size. Five patients (patient 1, 2, 7, 8, and 11) did not have any well-circumscribed lesions and were excluded from this analysis. In the other patients, we determined maximal lesion length and width as well as cortical thickness at the middle of the lesion’s length (Fig. 1). The inner border of the sclerotic rim surrounding a lesion was regarded as the limit of the lesion. To make up for effects of bone growth and technique-related differences in magnification, the width of a lesion was related to the width of the mid-shaft diaphysis of the same bone, and the length of the lesion was related to bone length. Cortical width at the site of the lesion was related to cortical width at the mid-shaft diaphysis of the same bone (Fig. 1).

Bone biopsy and histomorphometry

Transiliac bone samples were collected on d 4 or 5 after dual labeling with demeclocycline (15–20 mg/kg/d taken orally during two 2-d periods separated by a 10-d free interval). biopsy preparation and histomorphometric analyses were performed with the standard procedures used at the Shriners Hospital, as described previously (23). Measurements were carried out using a digitizing table with Osteomeasure software (Osteometrics Inc., Atlanta, GA). Nomenclature and abbreviations follow the recommendations of the American Society for Bone and Mineral Research (24). Specimens from FD patients were examined for the presence of a dysplastic fibrous lesion. Specimens with and without evidence for dysplastic tissue were analyzed separately (see Results). Results were compared with those of age-matched controls that were taken from our reference sample collection (23).

Statistical analysis

Comparisons between two groups were performed using Student’s unpaired t test or Mann-Whitney U test, as appropriate. Longitudinal differences between two time points within the same group of subjects were compared by paired t test or Wilcoxon’s test, as appropriate. The difference of densitometric results from the mean value of healthy subjects was tested for significance using the one-sample t test. All tests were two-tailed, and throughout the study, P < 0.05 was considered significant. These calculations were performed using the SPSS software, version 9.0 for Windows (SPSS Inc., Chicago, IL).

Results

Mineral metabolism

At baseline, serum total calcium levels, urinary calcium/cr. ratios and serum PTH levels were within or very close to the reference range in all patients. Serum 25-OH vitamin D concentrations were moderately low in four patients (19–32 nmol/liter; reference range 34–91 nmol/liter). Serum 1,25-(OH)₂ vitamin D levels were low in seven patients (between 25 and 55 pmol/liter; reference range, 65–134 nmol/liter) and were elevated in two patients (207 and 213 pmol/liter).

During the first 3 d of the initial infusion cycle, total serum calcium dropped by 0.32 ± 0.04 mmol/liter (mean ± se) to reach a nadir of 2.04 ± 0.02 mmol/liter. Serum calcium had returned to baseline values by the time the patients were readmitted for the second infusion cycle 4 months later. Fluctuations in serum calcium were smaller during subsequent treatment cycles (decreases of 0.23 ± 0.03 mmol/liter and 0.21 ± 0.02 mmol/liter during the second and third cycles, respectively). Hypocalcemia was not associated with clinical symptoms and was treated with oral calcium supplements. In no case was iv calcium therapy required.

The decrease in serum calcium was associated with an increase in serum PTH levels. PTH reached values up to twice the upper limit of the reference range on the third day of the first infusion cycle. However, levels consistently returned to pretreatment results by the time of the next treatment cycle. The transient rise in PTH levels was associated with the expected transient decrease in serum phosphorus (by 0.49 ± 0.08 mmol/liter) and an increase in 1,25-(OH)₂ vitamin D concentrations (by 87 ± 25%; n = 13).

Bone metabolism

Pretreatment alkaline phosphatase activity was above the age-related reference range in 17 of the 18 patients. Urinary NTX/creatinine ratios were above the age- and sex-specific 75th percentile in 12 patients (Fig. 2). On d 3 of the first infusion cycle, alkaline phosphatase and NTX/creatinine had decreased to 85 ± 3% and 51 ± 8% of the pretreatment value, respectively (in both cases P < 0.001 for difference to pretreatment results). Thereafter, alkaline phosphatase levels remained stable during the 4 months until the patients returned for the second infusion, whereas NTX/creatinine ratios increased slightly (to 67 ± 6% of the baseline result).

The long-term effects of pamidronate on bone metabolism were evaluated in the 13 patients who had received at least 3 yr of therapy (Fig. 3). Only those samples were used for this analysis that were obtained immediately before a treatment cycle. Both serum alkaline phosphatase and urinary NTX/creatinine remained persistently below the baseline level. After a rapid decrease in the first year of therapy, there was a continuous and less steep decline with time.

Fig. 1. Quantitative evaluation of dysplastic lesion size. Lesion length and width (arrows and short bars) as well as cortical thickness at the middle of the lesion’s length (not indicated) were measured on x-rays. The width of each lesion was related to the width of the mid-shaft diaphysis of the same bone (arrow), and the length of the lesion was related to bone length (not indicated). Cortical width at the site of the lesion was related to cortical width at the mid-shaft diaphysis of the same bone. A, Proximal femur of patient 13 at the start of pamidronate treatment. B, After 2.0 yr of treatment.
Radiology

There was no clear evidence of refilling of lytic lesions. In contrast, some lesions clearly increased in size during pamidronate therapy (Fig. 4). In the 13 patients with well-delimited lesions, there was a significant increase in lesion width even after correction for the width of unaffected bone ($P < 0.01$; Wilcoxon test). No significant changes were noted in lesion length related to bone length and in cortical width at the site of the lesion related to cortical width of unaffected bone ($P > 0.1$ in both cases). Limb and spine deformities did not regress. None of the patients had radiological signs of rickets at any time.

The long-term effect of pamidronate therapy on the size, mass, and density of unaffected bone was evaluated in the 10 patients who had received at least 3 yr of therapy and who did not have radiological evidence of a dysplastic lesion at the lumbar spine (Fig. 5). Bone size, as judged from the anteroposterior vertebral projection area was below the reference mean value at baseline ($P = 0.04$) but remained at a constant percentage of the value expected for age and sex. In contrast, BMC increased faster than in healthy children. These changes led to a significant increase in vBMD, which after 3 yr of treatment was 22% above the value expected for healthy children ($P = 0.003$).

Histomorphometry

The effect of pamidronate treatment on bone tissue was analyzed separately for dysplastic and unaffected bone. The results of pretreatment and treatment samples could not be analyzed in a longitudinal manner, because there was an insufficient number of specimen pairs consisting exclusively of affected or unaffected tissue, respectively. Therefore, histomorphometric data were evaluated in a cross-sectional fashion.

Iliac biopsy samples containing dysplastic bone tissue were obtained from nine patients who had not received pamidronate before biopsy and from seven patients who had been on pamidronate for a median time of 2.2 yr (Table 2; Fig. 6). Histomorphometric results were similar for treated and untreated patients. In particular, there was no detectable treatment effect on resorption parameters, and there was a similar accumulation of osteoid.

Iliac bone specimens containing only unaffected bone tissue were obtained from 12 patients who had received pamidronate for a median of 2.0 yr (Table 3). These samples were used to assess treatment safety, in particular to search for evidence of a mineralization defect during pamidronate therapy. Compared with age-matched controls, samples from FD patients had lower osteoid thickness, mineralizing surface per bone surface and mineralizing surface per osteoid.
surface. Mineral apposition rate and mineralization lag time were similar in the two groups. Three FD patients had prolonged mineralization lag time (above 25 d), but osteoid thickness was not increased in any patient. Thus, none of the patients fulfilled the histomorphometric criteria for osteomalacia (15).

**Growth**

Four severely affected patients had stopped growing before the start of pamidronate therapy and were extremely short (height z-scores between −5.5 and −9.9). Figure 7 shows height data in patients who were still growing when entering the study. Pretreatment height was within normal limits for most of these children. In the 14 growing patients who completed 1 yr of therapy, there was no significant change in height z-scores \( (P = 0.59, \text{Wilcoxon test}) \). Height z-scores also remained stable in the nine growing patients who received at least 3 yr of pamidronate therapy (median z-score at baseline: −1.4, range −8.1 to 0.4; after 3 yr of therapy: −1.5, range −8.4 to 0.7; \( P = 0.07 \)). Weight z-scores did not change significantly during this time \( (P = 0.26) \).

**Clinical course**

An acute phase reaction in the form of a flu-like syndrome developed in most patients during the first treatment cycle. The symptoms lasted for 24–48 h and resolved without complications. This reaction was similar to that noted in children with osteogenesis imperfecta (18).

During the follow-up period, seven patients had increasing coxa vara (shepherd’s hook) requiring orthopedic surgery. Mobility score improved from 2 to 3 in two patients and remained unchanged in the others. Two patients sustained two fractures, five had one fracture and the remainder had no fractures during the observation period. Pamidronate treatment did not have an obvious effect on bone healing after fracture or osteotomy.

**TABLE 2.** Histomorphometry of dysplastic bone tissue

<table>
<thead>
<tr>
<th></th>
<th>No. Treated</th>
<th>No. Untreated</th>
<th>( P )</th>
<th>Control (( n = 12 ))</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (yr)</td>
<td>7</td>
<td>9</td>
<td>0.42</td>
<td>12.0 ± 3.2</td>
</tr>
<tr>
<td>Bone structure</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bone volume per tissue volume (%)</td>
<td>7</td>
<td>26.8 ± 9.7</td>
<td>0.80</td>
<td>23.3 ± 4.2</td>
</tr>
<tr>
<td>Trabecular thickness (( \mu )m)</td>
<td>7</td>
<td>95 ± 50</td>
<td>0.93</td>
<td>143 ± 22</td>
</tr>
<tr>
<td>Trabecular number (per mm)</td>
<td>7</td>
<td>3.0 ± 0.6</td>
<td>0.98</td>
<td>1.6 ± 0.2</td>
</tr>
<tr>
<td>Bone formation</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Osteoid thickness (( \mu )m)</td>
<td>7</td>
<td>13.0 ± 5.8</td>
<td>0.21</td>
<td>6.6 ± 1.7</td>
</tr>
<tr>
<td>Osteoid surface per bone surface (%)</td>
<td>7</td>
<td>74 ± 16</td>
<td>0.76</td>
<td>26 ± 10</td>
</tr>
<tr>
<td>Osteoid volume per bone volume (%)</td>
<td>7</td>
<td>26 ± 22</td>
<td>0.60</td>
<td>2.5 ± 1.1</td>
</tr>
<tr>
<td>Osteoblast surface per bone surface (%)</td>
<td>6</td>
<td>28 ± 10</td>
<td>0.32</td>
<td>8 ± 4</td>
</tr>
<tr>
<td>Mineralizing surface per bone surface (%)</td>
<td>6</td>
<td>19 ± 7</td>
<td>0.77</td>
<td>13 ± 5</td>
</tr>
<tr>
<td>Mineral apposition rate (( \mu )m/d)</td>
<td>6</td>
<td>0.78 ± 0.22</td>
<td>0.83</td>
<td>0.87 ± 0.09</td>
</tr>
<tr>
<td>Bone formation rate per bone surface (( \mu )m/( \mu )m ( ^2 )d ( ^{-1} ))</td>
<td>6</td>
<td>60 ± 42</td>
<td>0.85</td>
<td>43 ± 17</td>
</tr>
<tr>
<td>Bone resorption</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Osteoclast surface per bone surface (%)</td>
<td>7</td>
<td>2.3 ± 1.1</td>
<td>0.91</td>
<td>0.87 ± 0.35</td>
</tr>
<tr>
<td>Eroded surface per bone surface (%)</td>
<td>7</td>
<td>14 ± 10</td>
<td>0.60</td>
<td>16 ± 5</td>
</tr>
</tbody>
</table>

Specimens from patients on pamidronate therapy (for a median of 2.2 yr; range, 1.4–4.8 yr) are compared with those from patients who had not received medical therapy before biopsy. Values from age-matched healthy controls are shown for comparison.

Values are mean ± SD or median (range). \( P \) values represent the significance of the difference between samples obtained from untreated and treated patients \( (t \text{ test}) \).
At the time of last follow-up, eight patients continued to receive pamidronate therapy. Pamidronate was discontinued in 10 patients after a treatment period ranging from 1.2–7.5 yr. Six of these patients felt that there was no more benefit of treatment, and they are without medical therapy since. The four other patients were enrolled in a trial of oral alendronate, after dysplastic lesions had continued to progress under pamidronate.

**Discussion**

In this observational study, we evaluated the effect of cyclical iv pamidronate therapy in children and adolescents with severe polyostotic FD. Although not quantitatively examined, pamidronate appeared to be effective in reducing bone pain, confirming earlier reports (7, 12, 13). However, we were unable to objectively demonstrate a positive therapeutic effect on the size or histological appearance of dysplastic lesions. This is consistent with the results of smaller series of pediatric FD patients, where no radiological evidence for refilling of dysplastic lesions was found (12, 13). Nevertheless, these results are somewhat disappointing, as Chapurlat et al. (7) had reported refilling of dysplastic lesions in about half of adult patients who underwent a similar treatment protocol.

It thus appears that there is a difference between the treatment effect in adults and in children. It is possible that FD lesions progress faster in young subjects than in adults and thus might be more difficult to control with medical therapy (5). The patients in our study may have been more severely affected than those of Chapurlat et al., as suggested by the considerable proportion of our patients who had hypophosphatemia. It can be speculated that pamidronate may have slowed down the expansion of lesions in our patients, even if it did not visibly improve them. This hypothesis can be tested only in a placebo-controlled study where subjects are closely matched for age and disease severity. It should be noted that the results reported in adults were not based on controlled studies either, leaving open the possibility that the reported refilling of dysplastic lesions reflected the natural evolution of the disorder rather than a true treatment effect.

One might assume that decreasing bone marker levels during pamidronate therapy indicate a slower activity of the dysplastic lesions. However, pamidronate does not specifically act on FD lesions, but also suppresses the turnover of unaffected bone tissue. It is difficult to judge whether changes in the levels of biochemical bone markers reflect more the effect of therapy on lesions or on unaffected bone. Our histomorphometric studies revealed decreased turnover in unaffected bone tissue during therapy, but did not demonstrate a treatment effect on the metabolic activity of dysplastic lesions.

Whereas the efficacy of pamidronate therapy is hard to prove, our observations suggest that this treatment approach is safe. Longitudinal growth was not affected, and lumbar spine bone size increased at a normal rate. This is consistent with our observations in patients with osteogenesis imperfecta (25, 26). The vBMD of unaffected lumbar spine vertebrae increased above the age- and sex-specific mean value but remained well below levels that are seen in osteopetrosis. Yet, one possible source of concern is the decreased bone
t turnover of unaffected bone tissue. The implications of chronically low bone turnover in growing children are unknown at present.

The effect of therapy on bone mineralization is an important consideration, because one 13-yr-old FD patient in the series of Chapurlat et al. (7) developed rickets during pamidronate therapy. In the present study, hypophosphatemia was commonly found in the pretreatment evaluation, confirming recently published findings (3). None of our patients developed radiological signs of rickets, even though each treatment cycle led to a further transient decrease in serum inorganic phosphorus concentrations. Osteomalacia is part of the histological picture of a dysplastic lesion (27), but we have shown earlier that this is independent of systemic serum phosphorus levels (15). There was no indication of a systemic mineralization defect during pamidronate treatment in patients that did not contain dysplastic lesions. Quite to the contrary, osteoid thickness was low during pamidronate therapy. This probably reflects the decreased bone turnover, similar to what can be observed in patients with osteogenesis imperfecta who receive pamidronate (28).

In conclusion, pamidronate treatment of children and adolescents with severe forms of polyostotic FD appears to be safe and reduces bone pain. In that respect, pamidronate certainly is beneficial. However, we found no clear evidence that pamidronate has an effect on dysplastic lesions in such patients. Unfortunately, no form of medical therapy has been shown to yield any better results. Glucocorticoids and 1,25(OH)2 vitamin D have been proposed as therapeutic agents based on in vitro data but have not yet been put to clinical test (29, 30). It is possible that a different bisphosphonate or a combination of drugs will have a more marked effect on dysplastic lesions than pamidronate. There clearly is a need to explore new treatment options for children and adolescents with polyostotic FD.

Acknowledgments

We thank Guy Charette and Joséé Dépot for technical assistance with biopsy sample processing, and Mark Lepik for preparing the figures. We are indebted to Milan Bayer (Charles University, Prague, Czech Republic) for help in the preliminary stages of the study.

Received January 10, 2003. Accepted June 14, 2003.

Address all correspondence and requests for reprints to: Frank Rauch, Genetics Unit, Shriner’s Hospital for Children, 1529 Cedar Avenue, Montréal, Québec, Canada H3G 1A6. E-mail: frauch@shriners.ucalgill.ca.

This study was supported by the Shriner’s of North America. C.M. is the Royal Children’s Hospital Foundation/Woolworths Scholar.

Current address for H.P.: Inherited Metabolic Diseases Section, Children’s Hospital and Department of Pediatrics, University of Nebraska, Omaha, Nebraska 68198-5430.

References